{"id":"chemotherapy-chop","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"10-20","effect":"Mucositis"},{"rate":"5-10","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"20-30","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOP combines cyclophosphamide (alkylating agent), doxorubicin (topoisomerase II inhibitor), vincristine (microtubule inhibitor), and prednisone (corticosteroid) to attack cancer cells through complementary pathways. This multi-drug approach increases efficacy against lymphomas by targeting different phases of the cell cycle and overwhelming cellular repair mechanisms. The regimen has been a standard-of-care treatment for decades, particularly in hematologic malignancies.","oneSentence":"CHOP is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:31.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma, diffuse large B-cell lymphoma"},{"name":"Hodgkin lymphoma"},{"name":"Other lymphoid malignancies"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06141772","phase":"NA","title":"Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2023-12-21","conditions":"Diffuse Large B Cell Lymphoma","enrollment":24},{"nctId":"NCT03473249","phase":"PHASE4","title":"Effectiveness of Contrast-Enhanced Ultrasound","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-05-09","conditions":"Abdominal Injuries, Physical Abuse, Accidental Fall","enrollment":120},{"nctId":"NCT04696692","phase":"NA","title":"Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2021-02-09","conditions":"Diffuse Large B-cell Lymphoma","enrollment":60},{"nctId":"NCT07262099","phase":"NA","title":"Study of Effects of Dao-yin Exercise on the Patients With Breast Cancer Post Operation and Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-01-13","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT00972478","phase":"PHASE1, PHASE2","title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-15","conditions":"Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":83},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT03505762","phase":"PHASE2","title":"Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-19","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT07057765","phase":"","title":"Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-05-05","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, Markers of Inflammation","enrollment":40},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":12},{"nctId":"NCT03995147","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-08-29","conditions":"B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell","enrollment":51},{"nctId":"NCT06742502","phase":"PHASE2","title":"Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":"Primary Mediastinal Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT01476787","phase":"PHASE3","title":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-12-29","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT05798156","phase":"PHASE2","title":"Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-03-20","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":125},{"nctId":"NCT02964858","phase":"NA","title":"Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2016-11","conditions":"NonHodgkin Lymphoma","enrollment":840},{"nctId":"NCT05350930","phase":"","title":"Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-06-09","conditions":"Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy","enrollment":38},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT04566887","phase":"PHASE2","title":"Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-01","conditions":"Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT06748521","phase":"PHASE2","title":"Dynamic CtDNA-guided Targeted Therapy in DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":108},{"nctId":"NCT03129828","phase":"PHASE1, PHASE2","title":"Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","status":"COMPLETED","sponsor":"Prof. Dr. Clemens Schmitt","startDate":"2017-03-17","conditions":"Diffuse Large B Cell Lymphoma","enrollment":38},{"nctId":"NCT06704555","phase":"PHASE2","title":"Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-20","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT02406092","phase":"PHASE3","title":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-13","conditions":"Non-Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT06674096","phase":"PHASE2","title":"RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-11-06","conditions":"Double-expressor Lymphoma","enrollment":44},{"nctId":"NCT04745832","phase":"PHASE3","title":"Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)","status":"TERMINATED","sponsor":"MEI Pharma, Inc.","startDate":"2021-08-13","conditions":"Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma","enrollment":82},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT00004112","phase":"PHASE3","title":"Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1999-09-01","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT02633137","phase":"PHASE2","title":"Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-12-14","conditions":"Mantle Cell Lymphoma, Untreated","enrollment":49},{"nctId":"NCT06569485","phase":"PHASE2","title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-23","conditions":"DLBCL","enrollment":38},{"nctId":"NCT00991211","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-01","conditions":"Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas","enrollment":549},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT03244176","phase":"EARLY_PHASE1","title":"Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Austin Health","startDate":"2017-07-21","conditions":"Lymphomas Non-Hodgkin's B-Cell","enrollment":28},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT05422066","phase":"PHASE2","title":"Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Li Zhiming","startDate":"2022-07-26","conditions":"DLBCL Germinal Center B-Cell Type","enrollment":50},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT06173999","phase":"PHASE1, PHASE2","title":"A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-12-22","conditions":"Peripheral T-cell Lymphoma","enrollment":100},{"nctId":"NCT05075460","phase":"PHASE3","title":"Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"T-cell Lymphoma","enrollment":107},{"nctId":"NCT00893516","phase":"PHASE2","title":"CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma","status":"TERMINATED","sponsor":"Emergent BioSolutions","startDate":"2007-05","conditions":"T-cell Lymphoma","enrollment":5},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT06347653","phase":"PHASE2","title":"Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)","status":"RECRUITING","sponsor":"Peking University","startDate":"2023-11-28","conditions":"Nodal T-follicular Helper Cell Lymphoma","enrollment":54},{"nctId":"NCT02636322","phase":"PHASE2","title":"Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-29","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable","enrollment":60},{"nctId":"NCT06289959","phase":"NA","title":"Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-25","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":30},{"nctId":"NCT03458546","phase":"PHASE1","title":"Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-21","conditions":"Lymphoma, B-Cell","enrollment":14},{"nctId":"NCT04263584","phase":"PHASE2","title":"Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"2020-06-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":62},{"nctId":"NCT06150053","phase":"","title":"Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL","status":"COMPLETED","sponsor":"University Hospital, Saarland","startDate":"2018-07-01","conditions":"DLBCL, Old Age; Debility","enrollment":79},{"nctId":"NCT00736450","phase":"EARLY_PHASE1","title":"Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2008-07-23","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":37},{"nctId":"NCT04660799","phase":"PHASE2","title":"A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-24","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":50},{"nctId":"NCT04928573","phase":"","title":"Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab","status":"COMPLETED","sponsor":"Libbs Farmacêutica LTDA","startDate":"2022-02-08","conditions":"Diffuse Large B Cell Lymphoma","enrollment":27},{"nctId":"NCT01902693","phase":"","title":"Prospective HIV Chemotherapy Cohort Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-10","conditions":"HIV, Cancer","enrollment":17},{"nctId":"NCT04692155","phase":"PHASE1, PHASE2","title":"Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2021-08-31","conditions":"Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT03542266","phase":"PHASE2","title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-06-01","conditions":"Previously Untreated Peripheral T-cell Lymphoma","enrollment":21},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT05376709","phase":"NA","title":"A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-09-01","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT00060346","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-10-05","conditions":"Lymphoma","enrollment":16},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT00217425","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-09-14","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT00129090","phase":"PHASE3","title":"Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2003-03","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":450},{"nctId":"NCT05874778","phase":"PHASE2","title":"A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-15","conditions":"Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy","enrollment":108},{"nctId":"NCT02555267","phase":"","title":"Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2015-09","conditions":"Lymphoma, Large B-cell, Diffuse","enrollment":148},{"nctId":"NCT03211702","phase":"","title":"Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2017-08-25","conditions":"Lymphoma, Large B-cell, Diffuse","enrollment":100},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD URIC ACID INCREASED"},{"count":1,"reaction":"MYALGIA"},{"count":1,"reaction":"NON-HODGKIN'S LYMPHOMA"},{"count":1,"reaction":"PAIN"}],"_approvalHistory":[],"publicationCount":152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CHOP"],"phase":"phase_3","status":"active","brandName":"chemotherapy (CHOP)","genericName":"chemotherapy (CHOP)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption. Used for Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, Other lymphoid malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}